

**IN THE CLAIMS:**

Please cancel claims 8-10 and 15-19 without prejudice Please enter the attached listing of claims into the application. This listing of claims replaces all prior listing of claims in the application.

**LISTING OF CLAIMS**

1. (Currently Amended) A compound selected from any one of 4-amino-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH<sub>2</sub> (~~SEQ ID NO:1~~); 4-amino-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH<sub>2</sub> (~~SEQ ID NO:2~~); 4-amino-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-D-Asp-NH<sub>2</sub> (~~SEQ ID NO:3~~); 4-amino-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-D-Thr-NH<sub>2</sub> (~~SEQ ID NO:4~~); 4-amino-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH<sub>2</sub> (~~SEQ ID NO:5~~); 4-amino-3-iodo-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH<sub>2</sub> (~~SEQ ID NO:6~~); 4-amino-3-iodo-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH<sub>2</sub> (~~SEQ ID NO:7~~); 4-amino-3-iodo-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH<sub>2</sub> (~~SEQ ID NO:8~~); 4-amino-3-iodo-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH<sub>2</sub> (~~SEQ ID NO:9~~); and D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH<sub>2</sub> (~~SEQ ID NO:10~~).
2. (Currently Amended) The compound of claim 1, wherein the compound comprises a di- or polyiodinated aromatic modification of a Tyr at position 3 of ~~SEQ ID NOs:1-10~~.
3. (Previously Presented) The compound of claim 1, wherein a radioactive element is linked to the compound.
4. (Original) The compound of claim 3, wherein the radioactive element is selected from the group consisting of <sup>188</sup>Re, <sup>186</sup>Re, scandium-47, copper-67, gallium-72, yttrium-90, iodine-125, iodine-131, samarium-153, gadolinium-159, dysprosium-165, holmium-166, ytterbium-175, lutetium-177, rhenium-186, rhenium-188, astatine-211 and bismuth-212.

5. (Previously Presented) The compound of claim 1, wherein the compound is linked to a cytotoxic molecule.
6. (Original) The compound of claim 5, wherein the cytotoxic molecule is selected from the group consisting of paclitaxel, doxorubicin or camptothecin.
7. (Original) The compound of claim 1, further comprising a pharmaceutically acceptable carrier.
- 8-10. (Cancelled).
11. (Original) A compound which selectively binds to SS receptor 2 (SST2) and/or SS receptor 5 (SST5), wherein the compound has a structure selected from the group consisting of (4-Amino)-D-Phe-c [Cys-Tyr-D-Trp-Lys-Val-Cys] –Thr-NH<sub>2</sub>, (4-Amino)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp- NH<sub>2</sub>, (4-Amino)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-D-Thr- NH<sub>2</sub>, (4-Amino)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-D-Asp-NH<sub>2</sub>, (4-Amino)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH<sub>2</sub>, (4-Amino-3-iodo)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH<sub>2</sub>, (4-Amino-3-iodo)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH<sub>2</sub>, (4-Amino-3-iodo)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH<sub>2</sub>, (4-Amino-3-iodo)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH<sub>2</sub>, and D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH<sub>2</sub>.
12. (Original) The compound of claim 11, further comprising a radioactive nuclide or a conjugating agent for linking to a cytotoxin.
13. (Previously Presented) A pharmaceutical composition comprising a mixture of a compound of claim 11 and at least one pharmaceutically acceptable carrier.
14. (Previously Presented) A pharmaceutical composition comprising an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

15-19. (Cancelled).